Harrow (HROW) Competitors

Prestige Consumer Healthcare (NYSE:PBH) and Harrow (NASDAQ:HROW) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, community ranking, risk and earnings.

Which has more risk and volatility, PBH or HROW?

Prestige Consumer Healthcare has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, Harrow has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.

Does the media prefer PBH or HROW?

In the previous week, Prestige Consumer Healthcare had 4 more articles in the media than Harrow. MarketBeat recorded 14 mentions for Prestige Consumer Healthcare and 10 mentions for Harrow. Harrow's average media sentiment score of 1.07 beat Prestige Consumer Healthcare's score of 1.02 indicating that Harrow is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prestige Consumer Healthcare	8 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harrow	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Do institutionals & insiders hold more shares of PBH or HROW?

99.9% of Prestige Consumer Healthcare shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 1.6% of Prestige Consumer Healthcare shares are held by company insiders. Comparatively, 13.7% of Harrow shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has higher earnings & valuation, PBH or HROW?

Prestige Consumer Healthcare has higher revenue and earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prestige Consumer Healthcare	$1.12B	3.77	$209.34M	$4.27	19.91
Harrow	$169.14M	5.52	-$24.41M	-$0.94	-27.88

Is PBH or HROW more profitable?

Prestige Consumer Healthcare has a net margin of 19.13% compared to Harrow's net margin of -19.75%. Prestige Consumer Healthcare's return on equity of 12.36% beat Harrow's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prestige Consumer Healthcare	19.13%	12.36%	6.39%
Harrow	-19.75%	-45.57%	-8.87%

Do analysts rate PBH or HROW?

Prestige Consumer Healthcare presently has a consensus target price of $93.33, indicating a potential upside of 9.79%. Harrow has a consensus target price of $61.50, indicating a potential upside of 134.64%. Given Harrow's stronger consensus rating and higher possible upside, analysts clearly believe Harrow is more favorable than Prestige Consumer Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prestige Consumer Healthcare	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Harrow	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community prefer PBH or HROW?

Prestige Consumer Healthcare received 405 more outperform votes than Harrow when rated by MarketBeat users. Likewise, 70.35% of users gave Prestige Consumer Healthcare an outperform vote while only 59.09% of users gave Harrow an outperform vote.

Company	Underperform	Outperform
Prestige Consumer Healthcare	Outperform Votes 496 70.35%	Underperform Votes 209 29.65%
Harrow	Outperform Votes 91 59.09%	Underperform Votes 63 40.91%

Summary

Prestige Consumer Healthcare beats Harrow on 11 of the 18 factors compared between the two stocks.